Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

Efficacy and safety data support potential of asenapine in the treatment of

schizophrenia and bipolar I disorder

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # 44 and # 80). Also presented were long-term safety and efficacy data from a clinical trial involving patients with schizophrenia and schizoaffective disorders.

Asenapine, a fast-dissolving, novel psychopharmacologic agent with a unique human receptor signature, was shown to be effective in two short-term bipolar mania studies with a nine-week extension and in two out of four short-term schizophrenia studies. In the third short-term schizophrenia study, neither asenapine nor the active control differentiated from placebo; in the fourth study, asenapine did not differentiate from placebo, while the active control did. Overall, asenapine was well tolerated in the Olympia trial program.

"Despite having effective treatments available, up to 75 percent of schizophrenia patients(1) and many bipolar disorder patients stop taking their medicines because of unwanted side effects or lack of efficacy," said Roger McIntyre, M.D., Associate Professor of Psychiatry and Pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. "Therefore, new therapies that are both effective and well-tolerated would be
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Jan. 19, 2011 RFID Journal features ... Someone can live or die depending on the ... agree leveraging better tracking of a drug,s expiration dates, ... levels, all performed in REAL TIME, would assist in ...
... PRINCETON, N.J., Jan. 18, 2011 Pharmasset, Inc. (Nasdaq: ... commenced an underwritten public offering, subject to market and ... pursuant to an effective shelf registration statement.  Of the ... the selling stockholders are selling 1,000,000 shares.  Pharmasset intends ...
Cached Medicine Technology:MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2Pharmasset Announces Proposed Public Offering of Common Stock 2Pharmasset Announces Proposed Public Offering of Common Stock 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted living ... p.m. to 4 p.m. on Feb. 13. , The community, which ... with physical disabilities between the ages of 22 and 64. , ... sweetheart-themed karaoke. , For more information about the event or Deer ...
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the ... final results of its separate concurrent fixed price exchange offers ... any and all of the approximately $118.9 million outstanding principal ... The Exchange Offers expired at 5:00 p.m., New York ...
... As President Obama prepares to sign a bill giving ... tobacco industry, a new study from Harvard School of ... continually changed the ingredients and the design of their ... acceptable product variance guidelines. The result, say the researchers, ...
... The Damon Runyon Cancer Research Foundation, a non-profit ... and innovative cancer research, named 17 new Damon ... Committee review. The recipients of this prestigious, three-year ... translational cancer research in the laboratories of leading ...
... in Williamson County ... Round Rock Medical Center today announced that the hospital will seek ... Williamson County. , , "St. David,s Round Rock Medical Center ... has the busiest emergency department in the City of Round Rock ...
... their choice , FRIDAY, June 19 (HealthDay News) -- ... can,t list any actual benefits, a new British study ... BMC Public Health , stemmed from interviews that University ... sports center. , "The majority of participants believed that ...
... WLP ) will release second quarter 2009 financial results on July 29, ... and its outlook during a conference call at 8:30 a.m. EDT that same ... its start with the following numbers: , , , ... 800-475-6701 (Domestic Replay), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 4Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 5Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 2Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 3Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 4Health News:WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29, 2009 2